PP405 may induce new hairgrowth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.
The conversation discusses a new hairgrowth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hairgrowth without disrupting the skin microbiome. sCD83 promotes hairgrowth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
Oleic acid, microneedling, and emu oil are discussed as potential hairgrowth treatments, with some users expressing skepticism about their effectiveness. Minoxidil and finasteride are recommended as current reliable treatments until more proven solutions are available.
Finasteride can cause gynecomastia, which may be reversible by stopping the drug and using selective estrogen receptor modulators (SERMs) like tamoxifen. Lifestyle changes such as weight loss and avoiding alcohol can also help, but surgery may be needed if the condition persists.